ERBB2 and breast cancer: We found that SCAN-B and GEO-combined dataset, breast cancer patients with high SGS also had a poor prognosis (Figure 3A, 3B), and the LumB, HER2-E and basal-like subtypes were the dominant molecular subtypes (Figure 3C, 3D).